Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 16, 2019 3:24pm
87 Views
Post# 29830422

RE:RE:Transcript of Dr. Jewett's AGM Presentation - June 2018

RE:RE:Transcript of Dr. Jewett's AGM Presentation - June 2018Considering the low kitty, that they are also presenting papers on the GBM indication (Ruvacare + Warbug effect on RG2 cells), it's almost a signal that they have a jv deal for the GBM indication.  Especially considering the latest PR posting and a senior financial position.

So a R/S doesn't make sense considering these hints/events.

A NASDAQ uplisting would make more sense around the publication of 3-month interim data of the first cohort treated @UHN.  Ph. 2b data would add to Ph. 1b p#5 and p#6 data.

The reason I say 3-month interim data will be published is that:

- 3-month is a first endpoint required by the new FDA guidelines and it is associated to a complete response (CR).  Dr. Kamat contributed to these new guidelines. 
- SESEN also published data at this 3-month milestone

Sesen Bio Shares Plunge Despite Reporting Positive 3-month Interim Phase III Results

May 22, 2018

Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.

On Monday Cambridge, Mass.-based Sesen said its antibody-drug conjugate (ADC) therapeutic Vicinium was able to help patients achieve a 42 percent complete response rate at three months. Patients in the trial had been previously treated with bacillus Calmette-Gurin (BCG) but have relapsed or did not respond to that first-line treatment. The three-month data from the Phase III trial was revealed at the American Urological Association Annual Meeting in San Francisco.
Bullboard Posts